Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
The study results may prompt doctors to choose vedolizumab over anti-TNF therapy as the first-line treatment for Crohn's disease.
Read Full NewsImmune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.
As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.
Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
1.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
2.
New First-Line Option for Advanced ALK-Positive Lung Cancer
3.
Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.
4.
There has been a new target found that might stop blood cancer.
5.
FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor
1.
Unraveling the Mysteries of Burkitt Lymphoma: A New Hope for Treatment
2.
Engineering the Future of Oncology with CAR- Natural Killer Cell Design & Therapeutics
3.
Case Study: The Role of Machine Learning in the Detection of Skin Cancer
4.
Unraveling the Complexities of Embryonal Carcinoma: A New Hope for Treatment
5.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
2.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
4.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
5.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge